Endovascular therapeutic hypothermia adjunctive to percutaneous coronary intervention in acute myocardial infarction: realistic simulation as a game changer.

Acute coronary syndrome (ACS) Coronary disease Educational debriefing Percutaneous coronary intervention (PCI) ST elevation myocardial infarction (STEMI) Simulation Therapeutic hypothermia Training

Journal

Reviews in cardiovascular medicine
ISSN: 1530-6550
Titre abrégé: Rev Cardiovasc Med
Pays: Singapore
ID NLM: 100960007

Informations de publication

Date de publication:
16 Mar 2022
Historique:
received: 27 11 2021
revised: 29 12 2021
accepted: 10 01 2022
entrez: 29 3 2022
pubmed: 30 3 2022
medline: 19 4 2022
Statut: ppublish

Résumé

Endovascular therapeutic hypothermia (ETH) reduces the damage by ischemia/reperfusion cell syndrome in cardiac arrest and has been studied as an adjuvant therapy to percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). New available advanced technology allows cooling much faster, but there is paucity of resources for training to avoid delays in door-to-balloon time (DTB) due to ETH and subsequently coronary reperfusion, which would derail the procedure. The aim of the study was to describe the process for the development of a simulation, training & educational protocol for the multidisciplinary team to perform optimized ETH as an adjunctive therapy for STEMI. We developed an optimized simulation protocol using modern mannequins in different realistic scenarios for the treatment of patients undergoing ETH adjunctive to PCI for STEMIs starting from the emergency room, through the CathLab, and to the intensive care unit (ICU) using the Proteus® Endovascular System (Zoll Circulation Inc™, San Jose, CA, USA). The primary endpoint was door-to-balloon (DTB) time. We successfully trained 361 multidisciplinary professionals in realistic simulation using modern mannequins and sham situations in divisions of the hospital where real patients would be treated. The focus of simulation and training was logistical optimization and educational debriefing with strategies to reduce waste of time in patient's transportation from different departments, and avoiding excessive rewarming during transfer. Afterwards, the EHT protocol was successfully validated in a trial randomizing 50 patients for 18 minutes cooling before coronary recanalization at the target temperature of 32 ± 1.0 ∘C or PCI-only. A total of 35 patients underwent ETH (85.7% [30/35] in 90 ± 15 minutes), without delays in the mean door-to-balloon time for primary PCI when compared to 15 control group patients (92.1 minutes versus 87 minutes, respectively; Realistic simulation, intensive training and educational debriefing for the multidisciplinary team propitiated feasible endovascular therapeutic hypothermia as an adjuvant therapy to primary PCI in STEMI. gov: NCT02664194.

Sections du résumé

BACKGROUND BACKGROUND
Endovascular therapeutic hypothermia (ETH) reduces the damage by ischemia/reperfusion cell syndrome in cardiac arrest and has been studied as an adjuvant therapy to percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). New available advanced technology allows cooling much faster, but there is paucity of resources for training to avoid delays in door-to-balloon time (DTB) due to ETH and subsequently coronary reperfusion, which would derail the procedure. The aim of the study was to describe the process for the development of a simulation, training & educational protocol for the multidisciplinary team to perform optimized ETH as an adjunctive therapy for STEMI.
METHODS AND RESULTS RESULTS
We developed an optimized simulation protocol using modern mannequins in different realistic scenarios for the treatment of patients undergoing ETH adjunctive to PCI for STEMIs starting from the emergency room, through the CathLab, and to the intensive care unit (ICU) using the Proteus® Endovascular System (Zoll Circulation Inc™, San Jose, CA, USA). The primary endpoint was door-to-balloon (DTB) time. We successfully trained 361 multidisciplinary professionals in realistic simulation using modern mannequins and sham situations in divisions of the hospital where real patients would be treated. The focus of simulation and training was logistical optimization and educational debriefing with strategies to reduce waste of time in patient's transportation from different departments, and avoiding excessive rewarming during transfer. Afterwards, the EHT protocol was successfully validated in a trial randomizing 50 patients for 18 minutes cooling before coronary recanalization at the target temperature of 32 ± 1.0 ∘C or PCI-only. A total of 35 patients underwent ETH (85.7% [30/35] in 90 ± 15 minutes), without delays in the mean door-to-balloon time for primary PCI when compared to 15 control group patients (92.1 minutes versus 87 minutes, respectively;
CONCLUSIONS CONCLUSIONS
Realistic simulation, intensive training and educational debriefing for the multidisciplinary team propitiated feasible endovascular therapeutic hypothermia as an adjuvant therapy to primary PCI in STEMI.
CLINICALTRIALS RESULTS
gov: NCT02664194.

Identifiants

pubmed: 35345271
pii: S1530-6550(22)00428-8
doi: 10.31083/j.rcm2303104
doi:

Banques de données

ClinicalTrials.gov
['NCT02664194']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104

Informations de copyright

© 2022 The Author(s). Published by IMR Press.

Déclaration de conflit d'intérêts

Michael Dae is a consultant for ZOLL Circulation Inc (San Jose, CA, USA). None of the other authors have conflicts of interest related to this article.

Auteurs

Luis Augusto Palma Dallan (LAP)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.
Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.

Michael Dae (M)

Department of Radiology, University of California, San Francisco, CA 94143, USA.

Natali Schiavo Giannetti (NS)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Tathiane Facholi Polastri (TF)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Marian Keiko Frossard Lima (MKF)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Carlos Eduardo Rochitte (CE)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Ludhmila Abrahao Hajjar (LA)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Claudia Yanet Bernoche San Martin (CYB)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Felipe Gallego Lima (FG)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Jose Carlos Nicolau (JC)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Mucio Tavares de Oliveira (MT)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Luis Alberto Oliveira Dallan (LAO)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Expedito Eustaquio Ribeiro da Silva (EE)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Roberto Kalil Filho (R)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Alexandre Abizaid (A)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Pedro Alves Lemos Neto (PA)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Sergio Timerman (S)

Department of Cardiology, InCor - Heart Institute, School of Medicine, University of Sao Paulo, 05403-900 Sao Paulo, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH